24.04.19 () 03:09

Dailypharm

X
"پ ...鿪׾ ⼺ "
뺴ö 2018-10-22 06:30:00
"پ ...鿪׾ ⼺ "
뺴ö 2018-10-22 06:30:00
÷ ãƼ[15] ڸ̿




 
"ۿ ּȭϰ, ɹĮǾǰ 鿪׾ ߷ ޴ ȯڵ鿡 ο Ǿ ٹ ϰ ͽϴ."

(47) ڸ̿ ϴ ü 鿪׾ ž ATB-301 ϼ ȣƮ(host) 鿪ýۿ ׼ TGF- ܹ ü 鿪ý ȭ ϼ Ȱ ϴ ġ.

ȯ ⺻ TGF-⸦ ϴ ִ. Ư , , ,  ȿ Ÿ ִ ӻ Ȯεǰ ִ.

ATB-301 ٽ TGF-Ⱑ ֱ ް ִ 鿪(Immune check point inhibitor) ๰׼ ٽ ǥʿ Immune check point inhibitor ȿ ų ִ key factor Ȯεǰ ִٴ ̴.

IL-2 ü 鿪 ׾ ۿ ϴ 'â' ϰ, Ʈ󺣴 TGF-⸦ Ͽ ϼ '' ȭ Ű ҷ ۿ ִ.

"ATB-301 TGF- Ʈ󺣴 鿪׾ IL-2 in-vitroin-vivo ȿ ̸ ϰ ֽϴ. Ϸ 1б⿡ ؿ GLP ȿ½ ȹԴϴ. 2019 ӻ 1 IIa Ϸ 2022 ̼ ƿ ǥ ϰ ֽϴ."

ATB-301 ฮ Ʈ󺣴 ϼ TGF- ϼ ȭ IL-2 T cell ϼ ݷ ȭ ٸ ۿ ๰ ׾ϱ ȭŲ. Ʈ󺣴 ü ӻ Ư ۿ Ƿ ۿ ׾ȿ شȭ ִ.

"ATB-301 Ʈ󺣴 IL-2 , ̹ 㰡 鿪׾ PD-1PD-L1 CTLA-4 Ȯ մϴ. ̿ ٸ 鿪׾ Ȯ ϸ ̴ ۿ뿡 ׾ȿ ų ˴ϴ."

IL-2 ϼ ϴ ȿ ƴϱ⿡ IL-2 Ȱȭ PBMC(peripheral blood mono-nuclear cell) ϸ ü IL-2 Ȱȭ ϼ ִ T شϴ ִ. in-vitro ϸ Ʈ󺣴 ܵ IL-2 Ȱȭ PBMC ܵ ϼ ȿ Ͱ Ͽ Ʈ󺣴 IL-2 뿡 ϼ ȿ Ǵ Ȯߴ.

Ϲϴ.

- »׿ Ź帳ϴ.

=ȭ п 縦 ġ ̱ SUNY Buffalo(ָб Buffalo ķ۽) Roswell Park Cancer Institute ȭС ڻ ߽ϴ.

忡 ִ Memorial Sloan-Kettering Cancer Center(MSKCC) 鿪׾ о߿ ڻ ׾ҽϴ.

ѱ ͼ ߿ ȸ JWũ ҿ ġ (׾, ڰ鿪ġ ), ؽſ DNA vaccine(ڱð() ġ) ܹ Ǿǰ ӻ ȹ  ֽϴ.

-ڸ̿  ֳ.

= ī ۷ι ۷ι ϰ, 2017 С索 ATB-101, ׾ ATB-301, ATB-301 鿪׾ TIPS å ϰ ֽϴ. 2018 9 Ҹ DZ ϸ鼭 ATB-301 Բ ü 鿪׾ ϰ ֽϴ.

-ڸ̿ ȭ ߰ ȭ Դϱ.

=ڸ̿ ȭ dzϰ, ϸ ȭ 㰡/డ žళ ޺κ ๰ ȸԴϴ. ž ȭ ɼ ǹմϴ. κ ̼ ü /ؿ 㰡áడ ȭ /ȭ ֽϴ.

-/索 ž ATB-101 Ȳ , Ը Ź帳ϴ.

=ATB-101 , 索 ġ ž GLP 4 ȿ½Ϸ, ġῡ п ȿ Ȯ߽ϴ. ̿ Ư Ϸ Դϴ. GLP 13 ݺ Ϸ Դϴ. ӻ 2 track ̸ ӻ 13 㰡 ޴ ȹ ְ(2019 ݱ IND ), ̱ ž 2󿡼 ٷ ̰ ĺʹ ڸ̿ (2019 ݱ ̱ IND ⡤ ǥ)Դϴ.

2022 Ϲݱ⿡ 㰡 Ϸᰡ ˴ϴ, 2023 ݱ డ Ϸ ǥ ֽϴ. Ը 索 70% , ATB-101 о 索 强 Ͽ 2023 ATB-101 ߸ 2~3 ̳ ۷ι 15000 ֽϴ.

-ATB-101 ֿ, ȯ, ٽ Դϱ.

=ATB-101 С索 ġ ġ а 索 ÿ ִ ȯڸ 1 ȿ ƴ϶ 鿡 ۿ ֽϴ. 1 о, 索 ̴ 3 ȿ ๰ 뿡 compliance ȿ ƴ϶ а ۿ뵵 ֽϴ.

-ATB-101 GLP ȿ½ ϱ.

=ġ ܵ ġ 索ġ ġᱺ ȿ ȿ Ȯϰ Դϴ.

  ATB-301 ĵ

-鿪׾ ž ATB-301 Ȳ , Ը Ź帳ϴ.

=ATB-301 TGF- Ʈ󺣴 鿪׾ IL-2 in-vitro/in-vivo ȿ ̸ ϰ ֽϴ. Ϸ 1б⿡ ؿ GLP ȿ½ ȹԴϴ. 2019 ӻ 1 IIa Ϸ 2022 ̼ ƿ ǥ ϰ ֽϴ.

۷ι ׾Ϻо Ը 2016 $113B 2021 $177B ˴ϴ. ۷ι ׾ ׾ġ , 缱ġ, ġ, а Ҿ 鿪ġᰡ ׾ġ ǥؿ ڸ Ǿǰ ߰ ̿ Ծ Ը Ŀ ֽϴ.

߿ Ʈ󺣴 Ÿ ϰ ҽų 2026 8, 2023 22 ˴ϴ.

-ATB-301 ȯ, ٽ Դϱ.

=ֿ δ ϼ host 鿪ýۿ ׼ TGF- ܹ , ü 鿪ý ׾ۿ ϰ ݴϴ. ȯ ⺻ TGF-⸦ ϴ , Ư , , ,  ȿ ǰ ֽϴ.

ٽ δ TGF-Ⱑ ֱ ް ִ 鿪(Immune check point inhibitor) ๰׼ ٽ ǥʿ Immune check point inhibitor ȿ ų ִ key factor ϴ. IL-2 ü 鿪 ׾ ۿ ϴ 'â' ϰ, Ʈ󺣴 TGF-⸦ Ͽ ϼ '' ȭ Ű ҷ ۿ ֽϴ.

-ATB-301 ฮ ġ ٰŴ Դϱ.

=ฮ Ʈ󺣴 ϼ TGF- ϼ ȭ IL-2 T cell ϼ ݷ ȭ ٸ ۿ ๰ ׾ϱ ȭŰ, Ʈ󺣴 ü ӻ Ư ۿ Ƿ ۿ ׾ȿ Ű Դϴ.

  Ʈ󺣴 IL-2 in-vitro

-ATB-301 Ȯ强 Ź帳ϴ.

=ATB-301 Ʈ󺣴 IL-2 , ̹ 㰡 鿪׾ PD-1/PD-L1 CTLA-4 Ȯ մϴ. ̿ ٸ 鿪׾ Ȯ ϸ ̴ ۿ뿡 ׾ȿ ų ˴ϴ.

-ATB-301 Ʈ󺣴 IL-2 in-VITRO ࿬ ¿.

=IL-2 ϼ ϴ ȿ ƴϱ⿡ IL-2 Ȱȭ PBMC(peripheral blood mono-nuclear cell) ϸ ü IL-2 Ȱȭ ϼ ִ T شϴ ֽϴ. in-vitro ϸ Ʈ󺣴 ܵ IL-2 Ȱȭ PBMC ܵ ϼ ȿ Ͱ Ͽ Ʈ󺣴 IL-2 뿡 ϼ ȿ Ǵ Ȯ߽ϴ.

- ȹ Դϱ?

= ڸ̿ ׾ ATB-301 Ʈ󺣴 ְ ǰ ٸ ׾ ڸ̿ ȸ 'Global Leader of Cancer Treatment' ǵ ּ ϰڽϴ. ׾ ġ  ׾ ġ ϸ ޴ ȯڵ鿡 ִ Դϴ.
뺴ö (sasiman@dailypharm.com) ٸ
  • μ
  • īī
  • ̽
  • Ʈ
  • 0
ñ
/home/dailypharm/issueData2017/
ǰ
0
͸ǰ | Ǹǰ߾ Ģ
ݱ

Ǹ ͸ , Ǹ ̸ ̵ ˴ϴ. ͸ ʸ ϸ, ͸ մϴ.

ڹ(-ڴϾ-ʱ ) ˵ ϸ ȸ Խ ⡯ ĺ Ʈ ׻ ֻܿ ˴ϴ. ο ø Ϲȸ Խ ĺ ڴϾ ȸ ϴܿ ǽð ˴ϴ.

뺸 ϰ ̵ ̿ Ǵ ֽϴ.

  • ۱ǡΰݱ Ÿ Ǹ ħϴ

    α׷ ϰ , ȳϴ Խù

    Ÿ Ǵ 3 ۱ Ÿ Ǹ ħ Խù

  • ٰ 桤 Ѽϴ Խù

    Ư ̿ ο ν 弳

    Ư 븳 ϴ

    Ȯ ȵ ҹ Ű

    弳 , Ӿ

    Ź, ɿ ˵Ǵ ( û )

    Ư ̳ ü ϴ

    Ư ѼϿ ش ûϴ

    Ư (ֹεϹȣ, ȭ, ּ ) Խϴ

    Ÿ ID Ȥ г ϴ

  • Խ Ư ѵǴ

    ʴ

    翡 ߺ

    κ Ͽ ݺ ϴ 쵵

    Խù,

    Ե Խù

    Խù б

  • û ִ

  • Ÿ

    ʿ伺 ̸

    Ÿ ˵Ǵ 縦

    Ÿ  ڰ ʿϴٰ ǴܵǴ

  • Ȯ

    ۱ڷκ , , ϴ

    Ÿ ʻ ħϰų ϴ

    翡 ̿ (Ÿ ID, йȣ )

  • ̻ Ϻ ׿ ̿ 縦 , Ρ ó ֽϴ.

    õ ̴ ҹ Ǵܵǰų ϸ 񽺿 ٶ ʴٰ ǴܵǴ ġ ϰڽϴ.

    رŸ ϸ ڿ ֽʽÿ. ּҴ dailypharm@dailypharm.comԴϴ.

ֽż ݴ
ٺ Ϲݾ ǸŰ (2024 04)
౹ 31
ǰ ְ
ѽŻ÷(10) 3,500 2,500 1,000 3,009
޾(100) 24,000 23,000 1,000 23,200
Ʒγΰ(100) 30,000 28,000 2,000 28,500
īɾ(10g) 7,000 6,000 1,000 6,559
Ľõ򿬰(5g) 5,000 4,500 500 5,138
Ź(4) 5,000 4,000 1,000 4,438
ڶ(20) 6,000 6,000 0 6,000
(10) 6,000 4,500 1,500 5,071
Ժ(10) 4,000 3,500 500 3,712
ڱ׸(20) 5,000 4,500 500 4,717
ť(10) 3,000 2,500 500 2,990
Ȱť(1) 1,200 900 300 1,182
Ǯɾ(3.3ml) 26,000 23,000 3,000 24,250
޵𿬰(10g) 7,000 5,900 1,100 6,289
öŸ(34) 13,000 11,000 2,000 11,866
뽺ī(20g) 22,000 18,000 4,000 20,184
ġ(1) 1,000 1,000 0 1,000
ӽ÷(21) 10,000 8,500 1,500 9,205
ͺ(10) 3,500 3,000 500 3,196
ݿ(1ڽ) 3,000 3,000 0 3,000
׶÷糪ƮŸ(6) 8,000 7,000 1,000 7,524
߽Ÿ(120) 70,000 50,000 20,000 60,385
Źĸ(10ĸ) 3,000 2,000 1,000 2,989
Ÿ̾(120) 60,000 50,000 10,000 51,538
տ(60ĸ) 29,000 25,000 4,000 27,600
Ÿ̷ER(6) 3,000 2,500 500 2,750
ٿ(30g) 12,000 9,000 3,000 11,444
(120) 25,000 22,000 3,000 24,991
Ʒ(6) 4,000 3,000 1,000 3,262
ǽõĸ(270ĸ) 110,000 110,000 0 110,000
B(120) 70,000 70,000 0 70,000
׳(10) 3,000 2,500 500 2,778
6̺(10) 3,000 3,000 0 3,000
(60) 230,000 220,000 10,000 223,333
Ⱦ 12,000 10,000 2,000 10,143
̰źĸ(60ĸ) 35,000 30,000 5,000 33,231
Ųť(20) 5,500 4,500 1,000 4,903
λ絹÷(100) 35,000 32,000 3,000 33,297
ü



ͳݽŹϹȣ: 00048 | 2005.09.09 | 2005.09.09 | : | : ȣ
ּ: ı 128 SK V1 GL ƮνƼ A 401ȣ
ȭ : 02-3473-0833 |ѽ : 02-3474-0169 | ûҳ⺸ȣå(å ű)
Contact dailypharm@dailypharm.com for more information
ϸ () ϴ ۱ǹ ˵Ǹ, 縦 ֽϴ.